Literature DB >> 8494873

Lp(a) lipoprotein and HLA-DR genotype in early coronary artery disease.

G H Dahlén1, L Slunga, G Holmlund, A Langö, B Lindblom.   

Abstract

The interest in Lp(a) lipoprotein [Lp(a)] has increased dramatically during the last few years due to the documented strong association between high Lp(a) levels and early atherosclerosis and its sequelae and the probable additional thrombogenic effect of inherited high Lp(a) levels. However, some paradoxes still remain to be solved in Lp(a) research. This pilot study was performed to test whether some criteria could be found for an association between Lp(a) levels, HLA genotype, and early coronary heart disease. If so, it could help to explain why some individuals with high Lp(a) levels get atherosclerosis while others with comparable lipid levels do not. It would also indicate that immunological processes could be involved in Lp(a) associated atherosclerosis. In this case-control study the HLA-DR genotypes 13 or 17 were significantly more frequently encountered in 30 male patients with early coronary heart disease than in 30 sex and age matched healthy controls (P = 0.012). These HLA-DR specificities were especially frequent in male patients with high Lp(a) levels. The same HLA-DR genotype pattern was not seen in 30 female patients, although there was a trend towards more frequent 13a genotype.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8494873     DOI: 10.1111/j.1744-313x.1993.tb00098.x

Source DB:  PubMed          Journal:  Eur J Immunogenet        ISSN: 0960-7420


  2 in total

1.  Association between HLA-DRB1, HLA-DRQB1 alleles, and CD4(+)CD28(null) T cells in a Chinese population with coronary heart disease.

Authors:  Wenjie Sun; Ying Cui; Lihui Zhen; Lijuan Huang
Journal:  Mol Biol Rep       Date:  2010-09-15       Impact factor: 2.316

2.  Association between LTA, TNF and AGER polymorphisms and late diabetic complications.

Authors:  Eero Lindholm; Ekaterina Bakhtadze; Corrado Cilio; Elisabet Agardh; Leif Groop; Carl-David Agardh
Journal:  PLoS One       Date:  2008-06-25       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.